Third-wave unlikely to be as severe as second wave: ICMR study | India News indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
A new Covid testing method, which involves gargling saline water, is expected to significantly cut RT-PCR test costs. However, a controversy has erupted with AIIMS and NEERI claiming that they first discovered the new method.
Mucormycosis not uncommon in India: Studies thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally.
New Delhi:
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author.